Human epidermal growth factor receptor 2 (HER2) therapy and anti-angiogenic agents are the only two biological targeted therapies that have improved OS in patients with gastric or gastroesophageal junction adenocarcinoma. This evidence concerns the gene ERBB2 and gastroesophageal junction adenocarcinoma.